REMD Biotherapeutics
REMD Biotherapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics for metabolic diseases, led by lead candidate Volagidemab (REMD-477), a glucagon receptor antibody in Phase II for Type 1 Diabetes.
- Company typePrivate
- Founded2012
- HeadquartersCamarillo, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What REMD Biotherapeutics does
REMD Biotherapeutics Inc. is a private, clinical-stage biopharmaceutical company founded in 2012 and headquartered in Camarillo, California. The company develops antibody-based therapeutics targeting metabolic diseases, with a primary focus on Type 1 Diabetes. Its lead clinical candidate, Volagidemab (REMD-477), is a monoclonal antibody that blocks the glucagon receptor to suppress dysregulated gluconeogenesis via the Cahill Cycle. Phase II results, published in Nature Medicine in October 2022, demonstrated meaningful reductions in insulin requirements and improved blood glucose levels in T1DM patients without increased hypoglycemia risk.
The company operates three proprietary technology platforms: the GPCR Antibody Platform for developing antibodies against G protein-coupled receptors, the SynermAb Bispecific Platform for engineering bispecific antibodies, and the TAI Platform for therapeutic antibody development. Global development and commercialization rights for bispecific antibodies generated through SynermAb have been licensed to GenScript ProBio under a 2020 agreement. The company co-developed BC008-1A, a bispecific antibody, with Buchang Biopharmaceutical, which received China NMPA IND approval in November 2022 for Phase 1 trials.
REMD's business model is partnership-driven rather than commercial. Revenue, when generated, is expected to come from licensing agreements, milestone payments, and eventual commercialization of drug candidates — none of which are currently disclosed. The company maintains a US parent entity (REMD Biotherapeutics Inc., California) and a wholly-owned China subsidiary (Beijing CoSci-REMD Bio Med-Tech Co., Ltd.) to support clinical operations in East Asia. The team is small (1–10 employees) and led by Co-Founder/CEO Hai Yan and Co-Founder/CSO Thomas Boone.
REMD Biotherapeutics firmographics
Firmographics- Name
- REMD Biotherapeutics
- Legal name
- REMD Biotherapeutics Inc
- Website
- https://remdbio.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- REMD Biotherapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics for metabolic diseases, led by lead candidate Volagidemab (REMD-477), a glucagon receptor antibody in Phase II for Type 1 Diabetes.
- Ownership category
- akta.pro rank
REMD Biotherapeutics industry classification
Industry- Product category
- Biopharmaceutical Antibody Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
- akta.pro secondary industries
- Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where REMD Biotherapeutics is headquartered
LocationHeadquarters
- HQ city
- Camarillo
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
REMD Biotherapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Distribution channels1 record
Marketing channels1 record
REMD Biotherapeutics product offering
Product offeringCore offering
REMD Biotherapeutics is a clinical-stage biopharmaceutical company that discovers and develops antibody-based therapeutics for metabolic diseases, with a primary focus on Type 1 Diabetes. Its lead clinical-stage candidate, Volagidemab (REMD-477), is a glucagon receptor antibody that has completed Phase II clinical trials demonstrating reduced insulin requirements and improved blood glucose levels. The company operates three proprietary technology platforms (GPCR Antibody Platform, SynermAb Bispecific Platform, and TAI Platform) which it leverages both for internal pipeline development and for licensing to pharmaceutical partners.
Product overview
REMD Biotherapeutics is a biopharmaceutical company developing antibody-based therapeutics for metabolic diseases, particularly diabetes. The company operates three technology platforms: the GPCR Antibody Platform for targeting G-protein coupled receptors, the SynermAb Bispecific Platform for bispecific antibody development, and the TAI Platform for targeted antibody therapeutics. The lead product candidate is REMD-477 (also known as Volagidemab or Vola), a glucagon receptor antibody that has completed Phase II clinical trials for type 1 diabetes. The company also has BC008-1A, a bispecific antibody developed in partnership with Buchang Pharmaceutical that received China NMPA IND approval for Phase 1 trials.
Differentiator
Problem solved
Functional benefit
Brands
- REMD-477 (Volagidemab, Vola): Glucagon receptor antibody therapeutic candidate for Type 1 Diabetes
- GPCR Antibody Platform
- SynermAb Bispecific Platform
- TAI Platform
Products and services
- REMD-477 (Volagidemab) A glucagon receptor antibody drug candidate developed by REMD Biotherapeutics for the treatment of Type 1 Diabetes. It blocks gluconeogenesis from the alanine-glucose cycle (Cahill Cycle) and has completed Phase II clinical trials demonstrating reduced insulin requirements and improved blood glucose levels without increased hypoglycemia risk.
- BC008-1A A bispecific antibody molecule jointly developed by REMD Biotherapeutics with Buchang Pharmaceutical, engineered using REMD's SynermAb Bispecific Platform. Received IND approval from China NMPA for Phase 1 clinical trials.
- SynermAb Bispecific Platform A proprietary bispecific antibody development platform enabling the engineering and production of dual-targeting antibodies, licensed to pharmaceutical partners (including GenScript ProBio for global rights) for co-development and commercialization of bispecific antibody therapeutics.
- GPCR Antibody Platform A proprietary antibody discovery platform focused on developing therapeutic antibodies against G protein-coupled receptor (GPCR) targets. Licensed/leveraged for partnerships and internal pipeline generation, including the lead candidate REMD-477 (glucagon receptor).
Quantifiable outcome
- Phase II clinical trial results published in Nature Medicine (2022) showed that glucagon receptor antibody REMD-477 treatment reduced insulin requirements and improved blood glucose levels in Type 1 Diabetes patients.
Companies that use REMD Biotherapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
REMD Biotherapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
REMD Biotherapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Buchang Biopharmaceutical (Buchang Pharmaceutical)coreBuchang Biopharmaceutical and REMD Biotherapeutics jointly developed a bispecific antibody molecule (BC008-1A). The partners, together with GenScript ProBio, received IND (Investigational New Drug) approval from China NMPA (National Medical Products Administration) for Phase 1 clinical trials of BC008-1A. This bispecific antibody was co-developed leveraging REMD's SynermAb Bispecific Platform.
- GenScript ProBiocoreGenScript ProBio and REMD Biotherapeutics entered into an exclusive strategic drug development collaboration. REMD licensed global rights to develop and commercialize bispecific antibodies generated using REMD's proprietary SynermAb Bispecific Platform to GenScript ProBio. This builds on an existing collaboration relationship and provides GenScript ProBio with access to REMD's bispecific antibody technology for global development.
- GenScript Biotech CorporationcoreGenScript Biotech Corporation, a world-leading bio-pharmaceutical CDMO (Contract Development and Manufacturing Organization), entered into an exclusive strategic drug development collaboration with REMD Biotherapeutics Inc. This partnership was the foundational collaboration that led to expanded agreements, including the September 2020 licensing deal for global bispecific antibody rights.
- Beijing CoSci-REMD Bio Med-Tech Co., Ltd. (CoSci-REMD Bio)coreBeijing CoSci-REMD Bio Med-Tech Co., Ltd. is the China-based subsidiary of REMD Biotherapeutics, incorporated in Beijing, China. The subsidiary is referenced in clinical trial announcements and corporate news releases, including the Phase 1b and Phase 2 clinical studies of REMD-477 (Volagidemab) for Type 1 Diabetes.
Recent moves6 records
Expansion highlights4 records
REMD Biotherapeutics competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
REMD Biotherapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
REMD Biotherapeutics leadership team
Management profileNumber of profiles
Profiles4 records
REMD Biotherapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
REMD Biotherapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
REMD Biotherapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about REMD Biotherapeutics
What does REMD Biotherapeutics do?
REMD Biotherapeutics is a clinical-stage biopharmaceutical company that discovers and develops antibody-based therapeutics for metabolic diseases, with a primary focus on Type 1 Diabetes. Its lead clinical-stage candidate, Volagidemab (REMD-477), is a glucagon receptor antibody that has completed Phase II clinical trials demonstrating reduced insulin requirements and improved blood glucose levels. The company operates three proprietary technology platforms (GPCR Antibody Platform, SynermAb Bispecific Platform, and TAI Platform) which it leverages both for internal pipeline development and for licensing to pharmaceutical partners.
Is REMD Biotherapeutics a public or private company?
REMD Biotherapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was REMD Biotherapeutics founded?
REMD Biotherapeutics was founded in 2012. It employs 1 to 10 people.
Where is REMD Biotherapeutics based?
REMD Biotherapeutics is headquartered in Camarillo, United States, in the North America region.
Does REMD Biotherapeutics have an API?
No public API is recorded for REMD Biotherapeutics.
What industry is REMD Biotherapeutics in?
REMD Biotherapeutics's product category is Biopharmaceutical Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.